Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA6 | P23280 | 2/20 | 0.46 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 4/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | EDNRB | P24530 | 1/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8071 | 0.81 | CA1 (0.62) | CA2CA1CA4CA6PLCG1 | |
| SCHEMBL29540971 | 0.81 | CA1 (0.62) | CA2CA1CA4CA6PLCG1 | |
| SCHEMBL10605529 | 0.81 | CA2 (0.50) | CA2CA1CA4CA6PLCG1 | |
| SCHEMBL31152920 | 0.80 | CA2 (0.45) | CA2CA1CA4CA6PLCG1 | |
| SCHEMBL25294557 | 0.80 | CA2 (0.45) | CA2CA1CA4CA6PLCG1 | |
| SCHEMBL528641 | 0.79 | CA2 (0.67) | CA2CA1CA4CA6PLCG1 | |
| SCHEMBL11257444 | 0.79 | TRPV4 (0.34) | CA2CA1CA4CA6PLCG1 | |
| SCHEMBL2163749 | 0.78 | CA1 (0.43) | CA2CA1CA4CA6PLCG1 | |
| SCHEMBL3234143 | 0.78 | EDNRB (0.37) | CA2CA1CA4CA6PLCG1 | |
| SCHEMBL2163747 | 0.78 | EDNRB (0.36) | CA2CA1CA4CA6PLCG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0576229-B1 | Low temperature process for preparing alpha-anomer enriched 2-deoxy-2, 2-difluoro-D-ribofuranosyl sulfonates | LILLY CO ELI (US) | 1997-12-17 | — | — | EP | claimed |
| US-5401861-A | CONTACTING A LACTOL WITH AN AMINE BASE, COOLING AND ADDING A SULFONATING REAGENT | ELI LILLY AND COMPANY (US) | 1995-03-28 | — | — | US | claimed |
| EP-0576229-A1 | Low temperature process for preparing alpha-anomer enriched 2-deoxy-2, 2-difluoro-D-ribofuranosyl sulfonates | ELI LILLY AND COMPANY (US) | 1993-12-29 | — | — | EP | claimed |
| EP-2176223-B1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI SA (FR) | 2013-01-23 | — | — | EP | disclosed |
| US-8143242-B2 | Malonamide derivatives with antithrombotic activity | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| US-7910686-B2 | Block copolymer and application thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| EP-2176223-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | Sanofi-Aventis (FR) | 2010-04-21 | — | — | EP | disclosed |
| US-20100047661-A1 | POLYMER LAMINATE MEMBRANE, THE METHOD FOR PRODUCING THE MEMBRANE AND THE USE OF THE MEMBRANE | SUMITOMO CHEMICAL COMPANY, LIMITED | 2010-02-25 | — | — | US | disclosed |
| US-7638220-B2 | Polymeric laminates, processes for producing the same, and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-12-29 | — | — | US | disclosed |
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| US-20030050315-A1 | Aryl sulfonyls as factor Xa inhibitors | WEXLER RUTH R (US) | 2003-03-13 | — | — | US | disclosed |
| US-20020187377-A1 | Reacting an aromatic diol with a disulfonylamine compound; membrane for fuel cell | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-12-12 | — | — | US | disclosed |
| EP-1248313-A2 | Polymer electrolyte and process for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-10-09 | — | — | EP | disclosed |
| US-6399644-B1 | ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY | 2002-06-04 | — | — | US | disclosed |
| EP-1175419-A2 | ARYL SULFONYLS AS FACTOR XA INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2002-01-30 | — | — | EP | disclosed |
| EP-1163221-A1 | SULFONAMIDE DERIVATIVES AS 5HT7 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000059902-A2 | ARYL SULFONYLS AS FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000056712-A1 | SULFONAMIDE DERIVATIVES AS 5-HT7 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-09-28 | — | — | WO | disclosed |
| US-4163005-A | FOR USE IN POLYMER COMPOSITIONS | VELSICOL CHEMICAL CORPORATION (US) | 1979-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050315-A1 | Aryl sulfonyls as factor Xa inhibitors | F12, F11, TFPI | CA2 2573/4885CA1 2249/4885CA4 2380/4885 |
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | F7, F9, TFPI | CA2 1258/4885CA1 1690/4885CA4 1140/4885 |
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | CTSB, CTSS, CTSF | CA2 212/4885CA1 1144/4885CA4 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.